Fine Organic Industries

BUY

Chemicals | Q3FY25 Result Update

CMP: Rs.3,874 | TP: Rs 5,500 | Upside 42%

Input cost surge impacts Q3

- FINEORG's Q3FY25 revenue of Rs5.1bn was in line with our estimates, however, EBITDA/PAT at Rs990mn/ 827mn came below due to higher input costs and opex. EBITDA margin at 19.3% (-492bps YoY/-599bps QoQ) was the lowest in the last 12 quarters.
- Capex of Rs7.5bn provides much-needed growth visibility beyond FY27E. This expansion will largely be self-funded (~Rs11bn cash on books). Resumption of operations at the Badlapur facility in Q3FY25 (disrupted since Q4FY24, by fire at adjacent plant) to aid volumes. Management is also evaluating greenfield capex in USA.
- FINEORG is operating at optimal utilizations with limited volume growth headroom till new capex comes onstream; although Patalganga facility (E73; 10ktpa) is still operating at low utilizations (to be absorbed over next couple of years). We trim our EPS estimates by 5-6% for FY25-27E to factor time-lag in pass through of higher input costs but reiterate 'BUY' rating with revised TP of Rs5500 (earlier Rs.6100; 33x FY27E EPS).

Q3FY25 performance impacted by lower exports and higher costs

Consolidated revenue came in at Rs5.1bn (+5%YoY/-14%QoQ), as higher volumes were offset by lower average realizations YoY. Standalone exports at Rs2.9bn were -20% QoQ/ +41% YoY, on weaker international demand sequentially, while domestic revenue at Rs2.3bn (+5% YoY/ -1% QoQ) remained steady. Gross margin came at 39.4% (-378bps YoY/ -335bps QoQ) due to increase in input costs caused by spike in certain vegetable oil prices; incremental costs will be passed through. EBITDA at Rs990mn (-16% YoY/ -34% QoQ) was impacted by adverse operating leverage, in addition to lower gross margin. PAT came at Rs827mn (-12% YoY/ -30% QoQ), aided by higher other income (+67% YoY/ +33% QoQ).

Large capex to enable future growth

FINEORG signed a 60-year lease agreement for land (~30 acres) at Jawaharlal Nehru Port Authority (JNPA) for its wholly owned subsidiary, Fine Organic Industries (SEZ) Private Limited. Capex outlay of Rs7.5bn to significantly increase its capacity (EC for ~70ktpa), in phases. Environmental clearance is awaited, post which 18-24 months required for commercial production (expected to begin by FY27). The products targeted are similar to the company's current portfolio, primarily targeting international markets (typically polymer additives heavy; high margin). Resumption of operations at Badlapur facility from Q3FY25, (shut since Jan'24) also provides scope for regaining lost volumes.



Key Data	
Nifty	22,929
Equity / FV	Rs 153mn / Rs 5
Market Cap	Rs 119bn
	USD 1.4bn
52-Week High/Low	Rs 5,959/ 3,900
Avg. Volume (no)	23,459
Bloom Code	FINEORG IN

	Current	Previous
Rating	BUY	BUY
Target Price	5,500	6,100
Change in Est	imates	

(Pahn)	Cur	rent	Chg (%)/bps		
(Rs.bn)	FY25E	FY26E	FY25E	FY26E	
Revenue	23	26	0.9	1.4	
EBITDA	5	6	(4.1)	(5.8)	
EBITDA (%)	23.9	22.5	(123)	(172)	
APAT	4	5	(5.4)	(5.5)	
EPS (Rs)	140.6	155.2	(5.4)	(5.5)	

Valuation (x)			
	FY25E	FY26E	FY27E
P/E	27.5	25.0	23.0
EV/EBITDA	19.7	18.5	15.8
ROE (%)	20.6	19.3	18.0
ROACE (%)	20.7	19 0	17 7

EV/EBITDA	19.7	18.5	15.8
ROE (%)	20.6	19.3	18.0
RoACE (%)	20.7	19.0	17.
Q3FY25 Result ((Rs Mn)		

Particulars	Q3FY25	YoY (%)	QoQ (%)
Revenue	5,132	5.1	(13.9)
Total Expense	4,142	11.9	(7.0)
EBITDA	990	(16.3)	(34.3)
Depreciation	130	(11.6)	5.0
EBIT	860	(16.9)	(37.8)
Other Income	291	66.6	32.7
Interest	4	(17.6)	(0.6)
EBT	1,146	(4.8)	(28.2)
Tax	319	26.5	(23.6)
RPAT	827	(12.2)	(29.6)
APAT	827	(12.2)	(29.6)
		(bps)	(bps)
Gross Margin	39.4	(378)	(335)
EBITDA (%)	19.3	(492)	(599)
NPM (%)	16.1	(318)	(360)
Tax Rate (%)	27.9	689	170
EBIT (%)	16.8	(444)	(644)

Director Research: Nitesh Dhoot

+9122 40969763 niteshd@dolatcapital.com

Associate: Nitin Raheja +91 222 40969623 nitinr@dolatcapital.com

Associate: Krushna Parekh +9122 40969755

krushnap@dolatcapital.com



Exhibit 1: Actual vs estimates

Particulars		Estimates		% Variation		Comment
(Rs mn)	Actual	Dolat	Consensus	Dolat	Consensus	Comment
Revenue	5,132	5,291	5,609	(3.0)	(8.5)	Revenue in-line with est. while EBITDA
EBITDA	990	1,303	1,303	(24.0)	(24.0)	was below estimates on increase in
EBITDA Margin (%)	19.3	24.6	23.2	(534 bps)	(394 bps)	input costs and higher opex.
PAT	827	1,028	1029	(19.6)	(19.6)	Fornings holow oot
EPS (Rs)	27.0	33.5	33.6	(19.6)	(19.6)	Earnings below est.

Source: Company, Dolat Capital

Exhibit 2: Change in estimates


Particulars		FY25E			FY26E			FY27E	
(Rs mn)	Old	New	Chg. (%)	Old	New	Chg. (%)	Old	New	Chg. (%)
Revenue	22,411	22,606	0.9	25,354	25,714	1.4	28,714	29,123	1.4
Change (%)	5.6	6.5		13.1	13.7		13.2	13.3	
EBITDA	5,638	5,408	(4.1)	6,136	5,780	(5.8)	7,065	6,661	(5.7)
Change (%)	5.6	1.3		8.8	6.9		15.1	15.2	
EBIT	5,065	4,836	(4.5)	5,466	5,110	(6.5)	6,023	5,620	(6.7)
Change (%)	6.0	1.2		7.9	5.7		10.2	10.0	
Adj. PAT	4,558	4,312	(5.4)	5,035	4,758	(5.5)	5,474	5,161	(5.7)
Change (%)	10.7	4.7		10.5	10.4		8.7	8.5	
EPS (Rs)	148.7	140.6	(5.4)	164.2	155.2	(5.5)	178.5	168.3	(5.7)

Source: Company, Dolat Capital




Quarterly trends

Exhibit 3: Weaker exports impact revenue; higher input costs impact GM




Source: Company, Dolat Capital

Exhibit 4: EBITDA declined 16% YoY/ 34% QoQ with margins at 19.3%



Source: Company, Dolat Capital

Exhibit 5: Key raw material prices trending higher



Source: Industry, Dolat Capital *Q3 data includes Oct and Nov'24



Financial Performance

Profit	and	Loss	Account	

(Rs Mn)	FY24A	FY25E	FY26E	FY27E
Revenue	21,230	22,606	25,714	29,123
Total Expense	15,889	17,198	19,933	22,461
COGS	12,170	13,068	15,465	17,463
Employees Cost	1,195	1,327	1,460	1,591
Other expenses	2,523	2,803	3,009	3,407
EBIDTA	5,340	5,408	5,780	6,661
Depreciation	561	572	671	1,042
EBIT	4,779	4,836	5,110	5,620
Interest	24	0	0	0
Other Income	719	863	1,035	1,035
Exc. / E.O. items	(6)	0	0	0
EBT	5,468	5,698	6,145	6,655
Tax	1,322	1,377	1,485	1,608
Minority Interest	0	0	0	0
Profit/Loss share of associates	(26)	(10)	98	114
RPAT	4,119	4,312	4,758	5,161
Adjustments	0	0	0	0
APAT	4,119	4,312	4,758	5,161
Balance Sheet				
(Rs Mn)	FY24A	FY25E	FY26E	FY27E
Sources of Funds				
Equity Capital	153	153	153	153
Minority Interest	0	0	0	0
Reserves & Surplus	19,057	22,544	26,440	30,649
Net Worth	19,210	22,697	26,593	30,802
Total Debt	0	0	0	0
Net Deferred Tax Liability	(108)	(108)	(108)	(108)
Total Capital Employed	19,102	22,589	26,485	30,694
Applications of Funds	·····		······	
Applications of Funds Net Block	2 227	2 052	4 202	0 000
CWIP	2,327 297	3,052	4,382	9,090 250
Investments	362	1,000 362	3,000 362	362
Current Assets, Loans & Advances	17,959	20,366	21,234	23,815
Current Investments	17,959	20,300	21,234	23,613
Inventories	2,609	3,097	3,522	3,750
Receivables	3,113	3,406	3,875	4,388
Cash and Bank Balances	10,485	12,101	11,988	13,734
Loans and Advances	1,143	1,143	1,144	1,145
Other Current Assets	609	619	704	798
Other Ourient Addets	000	013	704	7 30
Less: Current Liabilities & Provisions	1,842	2,191	2,492	2,823
Payables	1,354	1,548	1,761	1,995
Other Current Liabilities	488	643	731	828
sub total				
Net Current Assets	16,116	18,175	18,742	20,993
Total Assets	19,102	22,589	26,485	30,694
E – Estimates				

E – Estimates



Particulars (A) Margins (%) Gross Profit Margin	FY24A	FY25E	FY26E	F Y // F
				FY27E
	42.7	42.2	39.9	40.0
EBIDTA Margin	25.2	23.9	22.5	22.9
EBIT Margin	23.2	23.9	19.9	19.3
Tax rate	24.2	24.2	24.2	24.2
Net Profit Margin	19.4	19.1	18.5	17.7
(B) As Percentage of Net Sales (%)	13.4	19.1	10.5	17.7
COGS	57.3	57.8	60.1	60.0
Employee	5.6	5.9	5.7	5.5
Other	11.9	12.4	11.7	11.7
(C) Measure of Financial Status	11.9	12.4	11.7	11.7
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	196.4	0.0	0.0	0.0
Inventory days	45	50	50	47
Debtors days	54	55	55	55
Average Cost of Debt	17.9			
Payable days	23	25	25	25
Working Capital days	277	293	266	263
FA T/O	9.1	7.4	5.9	3.2
(D) Measures of Investment	0.1	7	0.0	0.2
AEPS (Rs)	134.3	140.6	155.2	168.3
CEPS (Rs)	152.7	159.3	177.1	202.3
DPS (Rs)	9.0	26.9	28.1	31.0
Dividend Payout (%)	6.7	19.1	18.1	18.4
BVPS (Rs)	626.6	740.3	867.4	1004.6
RoANW (%)	23.8	20.6	19.3	18.0
RoACE (%)	24.1	20.7	19.0	17.7
RoAIC (%)	50.4	50.6	40.9	35.7
(E) Valuation Ratios				
CMP (Rs)	3874	3874	3874	3874
Mcap (Rs Mn)	118,777	118,777	118,777	118,777
EV	108,292	106,676	106,789	105,043
MCap/ Sales	5.6	5.3	4.6	4.1
EV/Sales	5.1	4.7	4.2	3.6
P/E	28.8	27.5	25.0	23.0
EV/EBITDA	20.3	19.7	18.5	15.8
P/BV	6.2	5.2	4.5	3.9
Dividend Yield (%)	0.2	0.7	0.7	0.8
(F) Growth Rate (%)				
Revenue	(29.8)	6.5	13.7	13.3
EBITDA	(35.7)	1.3	6.9	15.2
EBIT	(39.0)	1.2	5.7	10.0
PBT	(35.1)	4.2	7.8	8.3
APAT	(33.4)	4.7	10.4	8.5
EPS	(33.4)	4.7	10.4	8.5



Cash Flow				
Particulars	FY24A	FY25E	FY26E	FY27E
Profit before tax	5,441	5,688	6,243	6,768
Depreciation & w.o.	561	572	671	1,042
Net Interest Exp	(642)	(863)	(1,035)	(1,035)
Direct taxes paid	(1,500)	(1,231)	(1,416)	(1,533)
Change in Working Capital	2,484	(589)	(747)	(580)
Non Cash	0	0	0	0
(A) CF from Operating Activities	6,345	3,578	3,715	4,662
Capex {(Inc.)/ Dec. in Fixed Assets n WIP}	(860)	(2,000)	(4,000)	(3,000)
Free Cash Flow	5,485	1,578	(285)	1,662
(Inc)./ Dec. in Investments	(3,513)	0	0	0
Other	466	863	1,035	1,035
(B) CF from Investing Activities	(3,906)	(1,137)	(2,965)	(1,965)
Issue of Equity/ Preference	0	0	0	0
Inc./(Dec.) in Debt	(274)	0	0	0
Interest exp net	(22)	0	0	0
Dividend Paid (Incl. Tax)	(276)	(825)	(862)	(952)
Other	(65)	0	0	0
(C) CF from Financing	(636)	(825)	(862)	(952)
Net Change in Cash	1,802	1,616	(112)	1,746
Opening Cash balances	5,148	6,951	8,566	8,454
Closing Cash balances	6,951	8,566	8,454	10,199
E. Edinolog				

E – Estimates

Notes



Stock Info and Rating History

Price Performance

Particulars	1M	3M	12M
Absolute (%)	(11)	(18)	(10)
Rel to NIFTY (%)	(10)	(16)	(14)

Shareholding Pattern

Particulars	Jun'24	Sep'24	Dec'24
Promoters	75.0	75.0	75.0
MF/Banks/FIs	11.1	11.6	11.5
FIIs	4.9	4.9	5.2
Public / Others	8.9	8.5	8.3



Month	Rating	TP (Rs.)	Price (Rs.)
Apr-24	BUY	5,250	4,355
May-24	BUY	5,450	4,287
Jun-24	BUY	5,800	4,698
Aug-24	BUY	6,000	5,172
Nov-24	BUY	6,100	4,711

*Price as on recommendation date

Notes



Dolat Rating Matrix

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Dolat Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747	
Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745	
CONTACT DETAILS				
Equity Sales	Designation	E-mail	Direct Lines	
Dinesh Bajaj	Director - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709	
Kapil Yadav	Director - Equity Sales & Corporate Access	kapil@dolatcapital.com	+9122 4096 9735	
Jubbin Shah	Director - Equity Sales	jubbins@dolatcapital.com	+9122 4096 9779	
Girish Raj Sankunny	Director - Equity Sales	girishr@dolatcapital.com	+9122 4096 9625	
Pratik Shroff	AVP - Equity Sales	pratiks@dolatcapital.com	+9122 4096 9621	
Rajeev Lala	AVP - Equity Sales	rajeevl@dolatcapital.com	+9122 4096 9767	
Equity Trading	Designation	E-mail		
P. Sridhar	Director and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728	
Chandrakant Ware	Director - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707	
Shirish Thakkar	Director - Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702	
Kartik Mehta	Director - Sales Trading	kartikm@dolatcapital.com	+9122 4096 9715	
Bhavin Mehta	Director Research - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705	



Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited, and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. persons only: This research report is a product of Dolat Capital Market Private Limited, under Marco Polo Securities 15a-6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Research reports are intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be affected through Marco Polo or another U.S. registered broker dealer.



Dolat Capital Market Private Limited.

Corporate Identity Number: U65990GJ993PTC116741

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE - INZ000274132, NSE - INZ000274132, Research: INH000014012

Regd. office: 1401-1409, Dalal Street Commercial, Block 53 (Bldg. No.53E) Zone-5, Road-5E, Gift City, Sector 9, Gandhinagar-382355 Gujarat, India.

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com